The collection and assessment of adverse reactions are important in the first decade after the marketing authorization of a drug. The information gathered in this period could help, for example, identify complications from its use that were unknown before its commercialization. However, when it comes to medicines that have been on the market for a long time there is general acceptance that their safety profile is already well-established and unknown adverse reactions unlikely to occur. Nevertheless, even older medicines, such as generic drugs, can generate new risks. For these drugs, a change in the safety profile could be the result of inadequate control of their quality, manufacturing, and distribution systems. And this is when pharmacovigilance comes in; to collect, detect, assess, monitor, and prevent adverse reactions with pharmaceutical products. This could help detect safety hazards and prevent the development of new complications that may arise due to a drug’s poor quality.
Read more about why pharmacovigilance should be crucial in being included in all phases of the drugs’ manufacturing and distribution process: https://journals.sagepub.com/doi/10.1177/20420986211038436?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed&